Union Strong Completes Hundreds of Millions RMB Series C Financing to Advance Comprehensive Digital and Intelligent Solutions for Stroke Diagnosis and Treatment

VCBeat (WeChat: vcbeat) has learned at the earliest opportunity that Union Strong (Beijing) Tech. Co. Ltd (hereinafter referred to as “Union Strong”), a leading domestic provider of integrated intelligent diagnosis and treatment solutions for stroke,^®” or the “Company”) announced the completion of a series of C and C+ round financing rounds totaling hundreds of millions of yuan, led by HongShan and jointly invested by POLY CAPITAL MANAGEMENT CO., LTD., Nuoyu Capital, Lehe Century, Jiufeite Capital, and the Tancer New Medical Fund. China Renaissance served as the exclusive financial advisor in this transaction. As a leader in the niche sector of intelligent diagnosis and treatment for stroke, the Company has gained recognition from numerous renowned investors who have continued to increase their investments.

In recent years, stroke has become the leading cause of death among the Chinese population. According to the "2019 China Stroke Prevention and Treatment Report" released by the Stroke Prevention and Control Project Committee of the National Health Commission, the lifetime risk of stroke in China ranks first globally at 39.9%, with a noticeable trend toward younger onset. Although millions of stroke cases receive clinical diagnosis and hundreds of thousands undergo clinical treatment annually, 99% of unruptured intracranial aneurysms (UIAs) remain undetected in clinical settings, and 70% of large vessel occlusions in acute ischemic stroke (AIS) fail to receive effective intervention. Patients who are not identified early or treated promptly face extremely high rates of mortality and disability following stroke onset. This not only imposes a severe burden on patients and their families but also places significant pressure on national healthcare insurance expenditures.

Union Strong^®Established in September 2016, the company has collaborated with numerous renowned neurology experts from leading hospitals across China, including Xuanwu Hospital, Beijing Tiantan Hospital, Changhai Hospital, and Huashan Hospital. Leveraging national-level and provincial/ministerial research projects such as the National Major Science and Technology Projects during the 13th Five-Year Plan period, and through years of rigorous scientific research and clinical validation, we have jointly developed an integrated intelligent diagnosis and treatment platform for hemorrhagic and ischemic stroke based on cutting-edge artificial intelligence algorithms. This platform provides AI-powered products and services covering the entire clinical pathway—from automated screening, precise diagnosis, and intelligent surgical planning to intraoperative assistance and postoperative follow-up—thereby comprehensively upgrading the standard of stroke care at hospitals of all levels in China through globally leading digital and intelligent solutions.

Union Strong^®Qin Lan, Founder and Chairmanstated: "China's healthcare industry is currently undergoing accelerated transformation. The centralized procurement and price reduction of drugs and consumables will significantly alleviate the medical burden on patients and the state, further promoting the inclusiveness and accessibility of healthcare. Meanwhile, the government is vigorously advancing priority approval processes for various innovative medical devices, aiming to foster high-quality, domestically originated and originally developed medical products. Union Strong^®As the first company in China to focus on an integrated AI solution for the prevention and emergency treatment of stroke, it possesses a comprehensive stroke product portfolio. Not only does it maintain global leadership in numerous algorithmic technologies, but through large-scale promotion and application, it also enables high-quality AI diagnostic and therapeutic services to reach primary healthcare settings. This ensures that tens of millions of cerebrovascular disease patients and nearly 100 million individuals at high risk of stroke in China receive more timely and effective treatment, thereby improving cure rates, reducing mortality and disability rates, and lowering overall medical expenditures.

Yang Yunxia, Partner at HongShanstated: “China currently has approximately 50 million individuals at high risk for stroke, creating a substantial demand for precise diagnosis and risk assessment among the affected population. A comprehensive AI-based solution for stroke will undoubtedly play a critical role throughout the entire continuum of care, including prevention, emergency response, diagnosis, and treatment. Union Strong^®“Collaborating with top domestic experts, we addressed critical pain points in treatment and extended our solutions upstream to intelligent screening and diagnosis, and downstream to patient follow-up assessment and smart therapy, thereby creating an integrated intelligent diagnosis and treatment platform for stroke.”

Li Wenxuan, Deputy General Manager of Poly Capitalstated: “For nearly 30 years since 1990, stroke has remained the leading cause of disease-related mortality in China. Union Strong^®Leveraging their own backgrounds in neurosurgery, the founding team has chosen stroke as the entry point to build a high-barrier product matrix covering the entire care continuum of “screening, diagnosis, treatment, and follow-up.” By focusing on the pain points of clinical departments, the company not only addresses the initial 0-to-1 challenges for physicians but also empowers them to achieve leaps from 1 to 2 and ultimately to 10. Moreover, we are even more bullish on Union Strong.^®"As a pioneer in the AI medical imaging sector, it will empower more primary care hospitals with its innovative business model, thereby enhancing China's capacity for the diagnosis and treatment of cerebrovascular diseases."

Yang Zhiwen, Partner at Nuoyu Capitalstates: “Union Strong^®An exceptional team; profound industry expertise in the field of neurosurgery; a comprehensive, closed-loop solution spanning risk assessment, treatment, and post-treatment monitoring for cerebrovascular diseases; rigorous business logic; and unparalleled execution capability—this is our impression of Union Strong.^®understanding, which is also the reason why we remain firmly bullish on them.”

Li Jin, Managing Director of China Renaissance, as the exclusive financial advisor for this transactionstated: “Union Strong^®“This is a company with which we established contact at a very early stage and have closely monitored over the long term. The growth of its founding team has paralleled the development of China’s neurointerventional industry. We greatly appreciate the founding team’s focus on the neurological field and their nearly 20 years of deep industry engagement, supporting physicians’ professional development. Their extensive industry experience and resources across multiple dimensions—including academic promotion, market education, hospital market access, and government affairs—are indispensable to the rapid development of the emerging field of medical AI. Furthermore, we are optimistic about the company’s product portfolio covering the entire diagnosis and treatment pathway for both hemorrhagic and ischemic diseases. By leveraging artificial intelligence to effectively address pain points in clinical diagnosis and treatment, the company delivers clear clinical value. Union Strong® is the leading company in the field of intelligent stroke diagnosis and treatment. We are pleased to once again assist the company in completing this additional round of financing. China Renaissance will continue to work closely with the company to accelerate its development, provide more high-quality products for clinical use, and benefit the vast number of cerebrovascular disease patients in China.”

HongShan is committed to helping entrepreneurs build enduring, great companies by bringing rich global resources and valuable historical experience to its portfolio companies. As “entrepreneurs behind entrepreneurs,” HongShan focuses on investment opportunities in technology, consumer, and healthcare sectors. Over the past 17 years, HongShan has invested in more than 900 companies with distinct technological features, innovative business models, and high growth potential.

Poly Capital is a private equity fund management company jointly established by Poly Developments and Holdings Group and Poly Investment Holdings Co., Ltd. The company commenced operations in December 2015 in the Hengqin Free Trade Zone of Zhuhai and currently maintains branches in Guangzhou, Beijing, Shanghai, and Shenzhen. Since its inception, Poly Capital has adhered to the corporate philosophy of “Value-Oriented, Prudent and Steadfast Execution.” By innovating unique methodologies and prioritizing investor value returns, the company leverages robust analytical capabilities and keen market insights to develop innovative project investment models. Deeply engaged in industrial capital, Poly Capital is committed to “serving a better life through technology investment.” Guided by the principles of specialization, refinement, distinctiveness, and novelty, it focuses primarily on three key sectors: construction technology, industrial enterprise services, and healthcare and elderly care.

Nuoyu Capital is a specialized investment firm focused on medical devices and digital health. Leveraging our long-term accumulation in medicine and the healthcare industry, we adhere to understanding the healthcare sector from the perspective of medicine itself, deeply cultivating the fertile ground of medical innovation, and identifying and supporting entrepreneurs who truly grasp the essence of medicine. Upholding the cooperative philosophy of trust, inclusiveness, support, and stewardship, we join hands with entrepreneurs to shape the future together.

Founded in 2014, Lehe Century is an industrial investment group co-established by a cohort of distinguished entrepreneurs and seasoned investors from the healthcare sector. The firm focuses primarily on key sectors including healthcare, new energy, and advanced manufacturing. Particularly in the healthcare domain, Lehe Century has successfully invested in numerous industry leaders and innovative enterprises since its inception, covering areas such as innovative drugs, medical devices, digital health, and healthcare supply chain services. Guided by the motto “Benevolence Endures, Harmony Achieves Success,” Lehe Century remains firmly optimistic about the historical opportunities and immense potential of China’s technological innovation. Committed to serving as a long-term partner for China’s new generation of outstanding innovators and entrepreneurs, the firm strives to empower continuous corporate innovation and development, jointly witnessing a bright future for technological innovation in China.

JiuFeiTe Capital is a professional private equity fund management company headquartered in Shenzhen. Established in June 2015, the firm currently manages six RMB-denominated equity investment funds. Adhering to a philosophy of refined investment, JiuFeiTe Capital focuses on equity investments in the pharmaceutical and healthcare, semiconductor, and major consumer sectors. To date, it has completed investments in nearly 20 projects, with multiple portfolio companies having successfully gone public or initiated IPO filing processes.

Probe Capital, established in 2017, is a boutique investment bank specializing in healthcare and life sciences. Its business portfolio encompasses financial advisory, direct investment, industry consulting, and innovation incubation. The founding team hails from leading private equity firms, financial advisory institutions, management consulting companies, and vertical healthcare media outlets. Since its inception, Probe Capital has consistently completed double-digit private financing and M&A transactions annually, with a cumulative transaction value approaching RMB 10 billion. In terms of value-added services for enterprises, the Probe Capital team possesses extensive and mature industry expertise. In 2020, Probe New Healthcare Fund was launched and has since invested in multiple leading companies within the sector.

China New Economy Investment Banker of the Year, Focus on Global TMT, Consumer and Health Three Major Industries. In addition to investment banking business, China Renaissance is managing a RMB fund and a US dollar fund. The company has branches in Beijing, Shanghai, Los Angeles and San Francisco and holds a license for the US securities market. The healthcare industry is an area where China Renaissance focuses and has deep advantages. It has been the new economy investment bank with the most health industry transaction records in China for four consecutive years. At the same time, China Renaissance has the largest scale, strongest professionalism and most complete industrial chain coverage of health industry investment banking teams in China.